
Meg Rebecca Gerstenblith MD
Assistant Professor, Dermatology, Case Western Reserve University School of Medicine
Join to View Full Profile
10755 Falls RoadPavilion I STE 350Lutherville, MD 21093
Phone+1 410-955-5933
Fax+1 410-367-2763
Dr. Gerstenblith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Dermatology, 2006 - 2009
University of Pennsylvania Health SystemInternship, Internal Medicine, 2004 - 2005
Johns Hopkins University School of MedicineClass of 2004
Certifications & Licensure
MD State Medical License 2009 - 2026
OH State Medical License 2010 - 2025
PA State Medical License 2004 - 2005
American Board of Dermatology Dermatology
Clinical Trials
- Post-Approval Study of MelaFind Start of enrollment: 2012 Nov 01
Publications & Presentations
PubMed
- Tumor microRNA signatures associate with stage II/III melanoma patient outcomes.Jennifer M Wiggins, Qiao Zhang, Yian Zhang, Fatemeh Vand-Rajabpour, Douglas Hanniford
Clinical Cancer Research. 2025-10-20 - 1 citationsDNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.Kathleen Conway, Sharon N Edmiston, Amanda Vondras, Allison Reiner, David L Corcoran
JCO Precision Oncology. 2024-11-01 - 7 citationsInterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.Irene Orlow, Keimya D Sadeghi, Sharon N Edmiston, Jessica M Kenney, Cecilia Lezcano
Plos One. 2023-01-01
Journal Articles
- Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell TransplantsJeffrey F Scott, Konstantin V Grigoryan, Jeremy S Bordeaux, Meg R Gerstenblith, Julia S Lehman, JAMA Dermatology
Authored Content
- Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell TransplantsApril 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









